Citation APA
Matikas, A., Naume, B., Wildiers, H., Sonke, G. G., Dieci, M. V., Karakatsanis, A., Andersson, A., Barnekow, E., Kessler, L. E., Einbeigi, Z., Killander, F., Linderholm, B. B., Schiza, A., Valachis, A., Nearchou, A., Engebraaten, O., Porojnicu, A., Soland, M. H., Mannsåker, B., Raj, S. X., Blix, E. S., Nordstrand, C. S., Lambertini, M., Vernieri, C., Punie, K., Sotiriou, C., Bergh, J., Villacampa, G., Zouzos, A., Hellström, M., Hartman, J., & Foukakis, T. (2025). Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE. BMJ open, 15(8), e102626. doi:10.1136/bmjopen-2025-102626
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/398092